Jim Miller joins C2 Pharma advisory board
.jpg)
Jim Miller joins C2 Pharma's advisory board.
Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, C2 Pharma, has expanded its advisory board with a new member.
Jim Miller, founder of PharmSource — a pioneering online database for contract manufacturing intelligence now run by Global Data — joins the board, which provides strategic guidance on company growth and progress via organic and M&A activities in the mid and long-term.
Miller is regarded as a biopharmaceutical contract manufacturing and development sector expert and is a frequent contributor to industry publications and events, as well as working as a consultant and a member of the Board of Advisors of C2 Pharma.
He joins existing members Dr Uwe Böhlke, Joachim Roeser, and Dr Jürgen Sackhoff.
"We are thrilled to expand our advisory board and align to gain their insight as we grow into a premier ophthalmic and niche active pharmaceutical ingredient (API) supplier with a unique virtual manufacturing model," said Andrew Badrot, CEO of C2 Pharma.
The announcement follows a recent expansion of the company’s API product portfolio with successful validation of Homatropine Hydrobromide and additions to the Digoxin API offering. Further R&D development and tech transfers are in process and are expected to be announced later this year.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.